Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. (January 2018)

• Record Type: Journal Article
• Authors: Fujii, Takeo; Matsuda, Naoko; Kono, Miho; Harano, Kenichi; Chen, Huiqin; Luthra, Rajyalakshmi; Roy-Chowdhuri, Sinchita; Sahin, Aysegul A.; Wathoo, Chetna; Joon, Aron Y.; Tripathy, Debu; Meric-Bernstam, Funda; Ueno, Naoto T.
• Is Part Of: European journal of cancer. Volume 89(2018)
• Page Start: 64
• Page End: 71
• Publication Date: 2018-01
• Subjects: Breast cancer -- Next-generation sequencing -- Somatic mutations -- TP53 -- PIK3CA -- Systemic therapy; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2017.11.015
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Background: Understanding the biology of breast cancer is important for guiding treatment strategies and revealing resistance mechanisms. Our objectives were to investigate the relationship between previous systemic therapy exposure and mutational spectrum in metastatic breast cancer and to identify clinicopathological factors associated with identified frequent somatic mutations. Methods: Archival tissues of patients with metastatic breast cancer were subjected to hotspot molecular testing by next-generation sequencing. The variables that significantly differed ( P < 0.05) in univariate analysis were selected to fit multivariate models. Logistic models were fit to estimate the association between mutation status and clinical variables of interest. Five-fold cross-validation was performed to estimate the prediction error of each model. Results: A total of 922 patients were included in the analysis. In multivariate analysis, previous systemic treatment before molecular testing (N = 186) was associated with a significantly higher rate of TP53 and PIK3CA mutations compared with the lack of systemic treatment ( P < 0.001 for both). Conclusion: Systemic treatment exposure is an independent risk factor for high rates of TP53 and PIK3CA mutation, which suggests the importance of testing samples after systemic therapy to accurately assess mutations. It is worth testing the gene profile when tumours become resistant to systemic treatments. Highlights: Treatment exposure is a risk factor for high rates of TP53 and PIK3CA mutations. The mutational status might change when patients are exposed to systemic therapy. It is worth testing the gene profile when tumours become resistant.